ArticleNeuro-oncology advances
Cerebrospinal fluid soluble protein tyrosine phosphatase receptor type Z detected with human natural killer-1 antibody as a practical biomarker for glioma diagnosis.
Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: A major challenge in managing gliomas is the lack of reliable and clinically applicable biomarkers. Imaging alone is often insufficient to distinguish gliomas from primary central nervous system lymphoma (PCNSL), necessitating invasive biopsy. Soluble protein tyrosine phosphatase receptor type Z (sPTPRZ) in cerebrospinal fluid (CSF) has recently emerged as a promising candidate. We evaluated the diagnostic utility of CSF sPTPRZ in differentiating gliomas from PCNSL. Methods: We developed an anti-HNK-1 antibody-based ELISA for CSF sPTPRZ and analyzed 51 glioma, 15 PCNSL, and 20 control patients. Complementary assays included western blotting, immunohistochemistry, qPCR. sPTPRZ immunopurified from glioma CSF was used to determine HNK-1 epitope sites. RNA-seq data from the C-CAT database were used to identify PTPRZ gene fusions. Results: CSF sPTPRZ levels were significantly elevated in glioma patients compared with both controls and PCNSL, demonstrating robust discrimination between these entities (AUC = 0.910 vs controls; AUC = 0.805 vs PCNSL; Conclusion: CSF sPTPRZ detection with anti-HNK-1 antibody is a minimally invasive biomarker for glioma. It significantly improves diagnostic discrimination from PCNSL, and provides a molecular rationale for biomarker-negative glioma subsets with PTPRZ-MET fusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.